Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1975 1
1977 1
1979 1
1980 2
1982 2
1983 1
1984 1
1985 2
1986 8
1987 4
1988 4
1989 7
1990 15
1991 7
1992 6
1993 8
1994 8
1995 10
1996 11
1997 7
1998 15
1999 10
2000 18
2001 6
2002 17
2003 20
2004 11
2005 11
2006 5
2007 8
2008 10
2009 12
2010 10
2011 8
2012 9
2013 4
2014 10
2015 7
2016 7
2017 5
2018 7
2019 5
2020 6
2021 7
2022 2
2023 5
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

318 results

Results by year

Filters applied: Meta-Analysis, Randomized Controlled Trial. Clear all
Page 1
Combined oral contraceptives: venous thrombosis.
de Bastos M, Stegeman BH, Rosendaal FR, Van Hylckama Vlieg A, Helmerhorst FM, Stijnen T, Dekkers OM. de Bastos M, et al. Cochrane Database Syst Rev. 2014 Mar 3;2014(3):CD010813. doi: 10.1002/14651858.CD010813.pub2. Cochrane Database Syst Rev. 2014. PMID: 24590565 Free PMC article. Review.
The relative risk of venous thrombosis for combined oral contraceptives with 30-35 mug ethinylestradiol and gestodene, desogestrel, cyproterone acetate, or drospirenone were similar and about 50-80% higher than for combined oral contraceptives with levonorgestrel. ...Risk …
The relative risk of venous thrombosis for combined oral contraceptives with 30-35 mug ethinylestradiol and gestodene, desogestrel, cypro
Hormonal Gender Reassignment Treatment for Gender Dysphoria.
Meyer G, Boczek U, Bojunga J. Meyer G, et al. Dtsch Arztebl Int. 2020 Oct 23;117(43):725-732. doi: 10.3238/arztebl.2020.0725. Dtsch Arztebl Int. 2020. PMID: 33559593 Free PMC article. Review.
Male-to-female treatment is carried out with 17beta-estradiol or 17beta-estradiol valerate in combination with cyproterone acetate or spironolactone as an antiandrogen, female-to-male treatment with transdermal or intramuscular testosterone preparations. ...
Male-to-female treatment is carried out with 17beta-estradiol or 17beta-estradiol valerate in combination with cyproterone acetate or …
A systematic review and meta-analysis of venous thrombosis risk among users of combined oral contraception.
Dragoman MV, Tepper NK, Fu R, Curtis KM, Chou R, Gaffield ME. Dragoman MV, et al. Int J Gynaecol Obstet. 2018 Jun;141(3):287-294. doi: 10.1002/ijgo.12455. Epub 2018 Feb 22. Int J Gynaecol Obstet. 2018. PMID: 29388678 Free PMC article. Review.
MAIN RESULTS: There were 22 articles included in the analysis. The use of COCs containing cyproterone acetate, desogestrel, drospirenone, or gestodene was associated with a significantly increased risk of VTE compared with the use of levonorgestrel-containing COCs (pooled …
MAIN RESULTS: There were 22 articles included in the analysis. The use of COCs containing cyproterone acetate, desogestrel, drospiren …
Interventions for female pattern hair loss.
van Zuuren EJ, Fedorowicz Z, Schoones J. van Zuuren EJ, et al. Cochrane Database Syst Rev. 2016 May 26;2016(5):CD007628. doi: 10.1002/14651858.CD007628.pub4. Cochrane Database Syst Rev. 2016. PMID: 27225981 Free PMC article. Review.
There were inconsistent results in the studies that evaluated laser devices (moderate to low quality evidence), but there was an improvement in total hair count measured from baseline.Further randomised controlled trials of other widely-used treatments, such as spironolactone, fi …
There were inconsistent results in the studies that evaluated laser devices (moderate to low quality evidence), but there was an improvement …
Effects of oral contraceptives on metabolic profile in women with polycystic ovary syndrome: A meta-analysis comparing products containing cyproterone acetate with third generation progestins.
Amiri M, Ramezani Tehrani F, Nahidi F, Kabir A, Azizi F, Carmina E. Amiri M, et al. Metabolism. 2017 Aug;73:22-35. doi: 10.1016/j.metabol.2017.05.001. Epub 2017 May 10. Metabolism. 2017. PMID: 28732568 Review.
In this meta-analysis the effects of the different durations (from 3months to 1year) of OC treatment using cyproterone acetate (CA) or third generation progestins on metabolic profile of patients with PCOS were assessed. ...
In this meta-analysis the effects of the different durations (from 3months to 1year) of OC treatment using cyproterone acetate (CA) o …
Different combined oral contraceptives and the risk of venous thrombosis: systematic review and network meta-analysis.
Stegeman BH, de Bastos M, Rosendaal FR, van Hylckama Vlieg A, Helmerhorst FM, Stijnen T, Dekkers OM. Stegeman BH, et al. BMJ. 2013 Sep 12;347:f5298. doi: 10.1136/bmj.f5298. BMJ. 2013. PMID: 24030561 Free PMC article. Review.
The relative risk of venous thrombosis for combined oral contraceptives with 30-35 g ethinylestradiol and gestodene, desogestrel, cyproterone acetate, or drospirenone were similar and about 50-80% higher than for combined oral contraceptives with levonorgestrel. ...
The relative risk of venous thrombosis for combined oral contraceptives with 30-35 g ethinylestradiol and gestodene, desogestrel, cyprote
Anti-Androgenic Effects Comparison Between Cyproterone Acetate and Spironolactone in Transgender Women: A Randomized Controlled Trial.
Burinkul S, Panyakhamlerd K, Suwan A, Tuntiviriyapun P, Wainipitapong S. Burinkul S, et al. J Sex Med. 2021 Jul;18(7):1299-1307. doi: 10.1016/j.jsxm.2021.05.003. J Sex Med. 2021. PMID: 34274044 Clinical Trial.
Testosterone and calculated free testosterone in the cyproterone acetate group were significantly lower than the spironolactone group. ...Serious adverse effects observed in cyproterone acetate users were drug-induced liver injury and asymptomatic hyperprolactinemia …
Testosterone and calculated free testosterone in the cyproterone acetate group were significantly lower than the spironolactone group …
Topical cyproterone acetate treatment in women with acne: a placebo-controlled trial.
Gruber DM, Sator MO, Joura EA, Kokoschka EM, Heinze G, Huber JC. Gruber DM, et al. Arch Dermatol. 1998 Apr;134(4):459-63. doi: 10.1001/archderm.134.4.459. Arch Dermatol. 1998. PMID: 9554298 Clinical Trial.
OBJECTIVE: To evaluate the clinical and hormonal response of topically applied cyproterone acetate, oral cyproterone acetate, and placebo lotion in women with acne. ...After topical cyproterone acetate treatment, serum cyproterone acetate concentration …
OBJECTIVE: To evaluate the clinical and hormonal response of topically applied cyproterone acetate, oral cyproterone acetate, …
A systematic review and meta-analysis of the association between cyproterone acetate and intracranial meningiomas.
Lee KS, Zhang JJY, Kirollos R, Santarius T, Nga VDW, Yeo TT. Lee KS, et al. Sci Rep. 2022 Feb 4;12(1):1942. doi: 10.1038/s41598-022-05773-z. Sci Rep. 2022. PMID: 35121790 Free PMC article.
The influence of exposure to hormonal treatments, particularly cyproterone acetate (CPA), has been posited to contribute to the growth of meningiomas. ...
The influence of exposure to hormonal treatments, particularly cyproterone acetate (CPA), has been posited to contribute to the growt …
318 results